<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37970745</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients.</ArticleTitle><Pagination><StartPage>e29235</StartPage><MedlinePgn>e29235</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29235</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Guangting</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6844-3949</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, The First People's Hospital of Chenzhou, Xiangnan University, Chenzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zanling</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Linlin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Cancer Center(Xiamen), Fudan University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jianqiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Med Virol. 2023 Jun;95(6):e28862. doi: 10.1002/jmv.28862</RefSource><PMID Version="1">37334978</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>12</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>16</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37970745</ArticleId><ArticleId IdType="doi">10.1002/jmv.29235</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Luo J, Zhang J, Tang HT, et al. Prevalence and risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong. J Med Virol. 2023;95:e28862.</Citation></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023;381:e74572.</Citation></Reference><Reference><Citation>Wang Y, Zhao D, Xiao W, et al. Paxlovid reduces the risk of long COVID in patients six months after hospital discharge. J Med Virol. 2023;95:e29014.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133-146.</Citation></Reference><Reference><Citation>Nordstr&#xf6;m P, Ballin M, Nordstr&#xf6;m A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022;399:814-823.</Citation></Reference><Reference><Citation>Ayoubkhani D, Bosworth ML, King S, et al. Risk of long COVID in people infected with severe acute respiratory syndrome coronavirus 2 after 2 doses of a coronavirus disease 2019 vaccine:&#xa0;community-based, matched cohort study. Open Forum Infect Dis. 2022;9:c464.</Citation></Reference><Reference><Citation>Launay O, Cachanado M, Luong Nguyen LB, et al. Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine. N Engl J Med. 2022;387:374-376.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>